⌕
Replimune Group Inc · REPL · Nasdaq
Tenet 24 · Weak
⇄ Compare
$13.29−0.16 (−1.17%)
Market open · 15-min delayed · as of 10:50 AM ET

Replimune Group Inc · Overview

Industry: Health Services · see every company filed here →

Replimune Group Inc scores 24/100. Weak. Quality is the soft spot versus 400 Healthcare peers. Insufficient inputs: Tenet 24 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=400
24/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
17
Quality
5
Health
51
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthCGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
no P/E on file
P/B
12.0×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
—
no P/S on file
ROE
−134%
TTM through Jun 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
5.23
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$1.3B
small cap
Div yield
0.00%
reinvests all
52-wk range
1.50 – 16.33
low → high

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

Tenets
3 / 17
  • ✕ Buffett Quality
  • ✕ Piotroski F-Score
  • ✕ Graham Defensive
  • ✓ Drawdown Context
  • ~ Reversal Evidence
  • ✕ Not-a-Value-Trap Gate
+11 more →
Financials
Revenue, margins and the five-year statements.
Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.
Statistics
ROIC−157%
Debt / equity1.00
Technical Analysis
Uptrend short-term signal
vs 50-day+1.8%
vs 200-day+50.8%
RSI (14)51
News & Insights
Headlines are on the News tab.
Dividends
0.00% yield

Pays no dividend. Every dollar of profit is reinvested into the business.

Ownership
259 13F filers

Holdings are on file. The share count they would be divided by is unverified, so the percentage is withheld.

About Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The…

Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

Free account: the funds that hold REPL, and at what weight. Everything else on this page stays open.Create a free account
Methodology© 2026 Tenet Investing Inc. · Toronto, Canada

Data from Intrinio and Financial Modeling Prep.